ABL Diagnostics Unveils Advanced HIV Drug Resistance Detection Platform at European Meeting
Key Insights
ABL Diagnostics (search) presented breakthrough data on MicrobiocheK® (search), an automated bioinformatics platform for comprehensive viral genome analysis including HIV-1 (search), RSV (search), Hepatitis Delta (search), Influenza (search), and SARS-CoV-2 (search).
The company demonstrated superior HIV-1 (search) drug resistance detection using the MGI (search) DNBSEQ-E25 sequencing platform, achieving 100% concordance with traditional methods for mutations above 5%.
The DNBSEQ-E25 platform showed enhanced sensitivity for detecting minority mutations (3-20%) linked to drug resistance, outperforming traditional Illumina platforms in Q30 scores.
ABL Diagnostics (search), a Euronext-listed molecular diagnostics company, presented two significant scientific advances at the European Meeting on HIV & Hepatitis 2025 in Barcelona, Spain. The presentations showcased breakthrough innovations in automated viral genome analysis and HIV drug resistance detection using next-generation sequencing technologies.
Advanced Bioinformatics Platform for Viral Genome Analysis
The company unveiled MicrobiocheK® (search), an advanced bioinformatics platform engineered for complete genome analysis of key viral pathogens including HIV-1 (search), RSV (search) A/B, Hepatitis Delta (search), Influenza (search) A/B, and SARS-CoV-2 (search). The platform integrates automated workflows for data processing, quality control, alignment, and variant calling, providing real-time access to curated HIV variant databases including Stanford, ANRS, Rega, and Geno2pheno.
The platform operates on a secure cloud-based infrastructure compliant with HDS (Healthcare Data Hosting) standards and offers seamless interoperability with Nadis®, a specialized electronic medical record system used in over 200 hospitals in France for HIV and Hepatitis patient management.
Results demonstrated the platform's high scalability, rapid deployment capabilities, and accurate detection of subtypes and mutations, including SARS-CoV-2 (search) and RSV (search) clades, even across large datasets. The clinical reporting features provided actionable insights for healthcare professionals.
"MicrobiocheK® (search) proves that automation, scalability, and security can coexist in a single platform designed for modern-day genomic surveillance. This marks a major advancement for real-time, clinically relevant viral genome analysis," said Dr. Sofiane Mohamed, Head of Research & Development at ABL Diagnostics (search).
Superior HIV Drug Resistance Detection Technology
ABL Diagnostics (search) presented the first evaluation of the DNBSEQ-E25 (MGI (search)) platform in detecting HIV-1 (search) drug-resistant minority variants using DeepChek® (search) HIV assays and QCMD reference samples. The study revealed several key performance advantages over existing technologies.
The DNBSEQ-E25 platform demonstrated high sequencing accuracy, with Q30 scores outperforming traditional Illumina platforms. The system achieved full genotyping and subtype identification across B, C, 02_AG, and 57_BC forms, with 100% concordance across MGI (search) and Illumina platforms for drug resistance mutations above 5%.
Notably, the DNBSEQ-E25 showed superior sensitivity in detecting minority mutations ranging from 3-20% that are linked to drug resistance, a critical capability for early detection of treatment resistance.
"Our data confirm that MGI (search)'s E25 platform, combined with DeepChek® (search) assays, is not only equivalent but in some aspects superior to existing technologies. It is a powerful tool for expanding access to NGS-based resistance testing in routine clinical settings," added Dr. Sofiane Mohamed.
Expanding Molecular Diagnostics Portfolio
ABL Diagnostics (search) specializes in proprietary molecular biology assays and end-to-end solutions for precise molecular detection and genotyping through two main product lines: UltraGene (search) for real-time PCR-based molecular detection and DeepChek® (search) for DNA sequencing and genotyping.
The company's growing portfolio covers HIV diagnostics including drug resistance assays and a Whole Genome Kit, SARS-CoV-2 (search), Tuberculosis (search), and Hepatitis B (search) & C advanced genotyping and drug resistance analysis, as well as microbiome and taxonomy analysis using 16s/18s RNA-based methods. The company has also expanded into syndromic real-time PCR assays and digital solutions including the Nadis® EMR system.
Based in Woippy, France, ABL Diagnostics (search) is publicly traded on compartment B of Euronext's regulated market in Paris under the ticker ABLD.